CoChat

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension

Open access
Frost, Adaani E., Barst, Robyn J., Hoeper, Marius M., Chang, Hyuk-Jae, Frantz, Robert P., Fukumoto, Yoshihiro, Galié, Nazzareno, Hassoun, Paul M., Klose, Hans, Matsubara, Hiromi, Morrell, Nicholas W., Peacock, Andrew J., Pfeifer, Michael, Simonneau, Gérald, Tapson, Victor F., Torres, Fernando, Dario Vizza, Carmine, Lawrence, David, Yang, Wei, Felser, James M., Quinn, Deborah A., Ghofrani, Hossein-Ardeschir · 2015 · The Journal of Heart and Lung Transplantation
Cited by 148

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial hypertension (PAH) patients inadequately responsive to 2 to 3 PAH-specific therapies. METHODS: The long-term (up to 204 weeks) safety and efficacy of imatinib in this open-label extension study were reviewed until early study termination on April 16, 2014. Of 202 IMPRES-enrolled patients, 66 imatinib and 78 placebo recipients entered the extension. RESULTS: Overall, 93.8% (135 of 144) of patients discontinued the extension study; administrative issues (i.e., sponsor termination; 32.6%) and adverse events (31.3%) were the primary reasons for discontinuation. Nine patients completed the extension study before it was terminated. Serious and unexpected adverse events were frequent. These included 6 subdural hematomas in the extension study and 17 deaths during or within 30 days of study end. Although the patients who tolerated imatinib and remained in the extension for a longer duration did experience an improvement in functional class and walk distance, most discontinued the drug and the study. CONCLUSIONS: Severe adverse events, significant side effects, and a high discontinuation rate limit the utility of imatinib in the treatment of PAH. These risks outweigh any possible improvements in hemodynamics and walk distance seen in those patients able to remain on drug. The off-label use of this compound in PAH is discouraged.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2015.05.025

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 148

Metadata

Authors
Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H.-J., Frantz, R. P., Fukumoto, Y., Galié, N., Hassoun, P. M., Klose, H., Matsubara, H., Morrell, N. W., Peacock, A. J., Pfeifer, M., Simonneau, G., Tapson, V. F., Torres, F., Dario Vizza, C., Lawrence, D., Yang, W., Felser, J. M., Quinn, D. A., & Ghofrani, H.-A.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2015-11
Volume
34
Issue
11
Pages
1366-1375
ISSN
1053-2498 (ISSN-L)
OpenAlex
W1929000169
Cited by
148
References
3
FWCI
11.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1016/j.healun.2015.05.025
The paper
Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H.-J., Frantz, R. P., Fukumoto, Y., Galié, N., Hassoun, P. M., Klose, H., Matsubara, H., Morrell, N. W., Peacock, A. J., Pfeifer, M., Simonneau, G., Tapson, V. F., Torres, F., Dario Vizza, C., Lawrence, D., Yang, W., . . . Ghofrani, H.-A. (2015). Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2015.05.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.